The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials

Seminars in Neonatology

Volumn 6, Issue 1, 2001, Pages 63-73

  Knight, David B ^a  

^a NATIONAL WOMEN S HOSPITAL   (New Zealand)

Author keywords

Indomethacin; Meta analysis; Newborn; Patent ductus arteriosus

Indexed keywords

ACETYLSALICYLIC ACID; DIGOXIN; FUROSEMIDE; IBUPROFEN; INDOMETACIN; MEFENAMIC ACID;

ARTERY LIGATION; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART LEFT RIGHT SHUNT; HEART OUTPUT; HUMAN; INFANT; LUNG COMPLIANCE; LUNG DYSPLASIA; MORTALITY; NECROTIZING ENTEROCOLITIS; NEWBORN; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RETROLENTAL FIBROPLASIA; REVIEW;

EID: 0035147665     PISSN: 10842756     EISSN: None     Source Type: Journal    
DOI: 10.1053/siny.2000.0036     Document Type: Article

References (62)

1. Early determinants of right and left ventricular output in ventilated preterm infants
2. Patent ductus arteriosus: How important to which babies
3. Effect of patency of the ductus arteriosus on blood pressure in very preterm infants
4. Effect of patent ductus arteriosus on left ventricular output in premature infants
5. Stroke volume and left ventricular output in preterm infants with patent ductus arteriosus
6. Assessment of ductus arteriosus shunt in preterm infants supported by mechanical ventilation: Effect of interatrial shunting
7. Longitudinal changes in the diameter of the ductus arteriosus in ventilated preterm infants: Correlation with respiratory outcomes
8. Hemodynamic significant PDA: An echocardiographic and clinical assessment of incidence, natural history, and outcome in very low birth weight infants maintained in negative fluid balance
9. Pulmonary function in preterm infants following treatment with intravenous indomethacin
10. Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome. Effects on pulmonary compliance and ventilation
11. Improved lung compliance following indomethacin therapy in premature infants with persistent ductus arteriosus
12. Pulmonary effects of closure of patent ductus arteriosus in premature infants with severe respiratory distress syndrome
13. Lung compliance in newborns with patent ductus arteriosus before and after surgical ligation
14. Improved lung compliance after ligation of patent ductus arteriosus in hyaline membrane disease
15. Indomethacin therapy on the first day of life in infants with very low birth weight
16. Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight infants
17. Prophylactic indomethacin (I) for the prevention of patent ductus arteriosus (PDA)
18. Early administration of indomethacin to preterm infants
19. Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin
20. Early prophylactic indomethacin prolongs respiratory support in very low birth weight infants
21. Administration of indomethacin for the prevention of periventricular-intraventricular hemorrhage in high-risk neonates
22. Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates
23. Prophylactic indomethacin for the prevention of intraventricular hemorrhage in preterm infants
24. Indomethacin reduces the risks of severe intraventricular hemorrhage
25. Prophylactic indomethacin therapy on the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room
26. Low-dose indomethacin and prevention of intraventricular hemorrhage: A multicenter randomized trial
27. Low-dose indomethacin therapy and extension of intraventricular hemorrhage: A multicenter randomized trial
28. A randomized, controlled trial of very early prophylactic ligation of the ductus arteriosus in babies who weighed 1000 g or less at birth
29. Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome
30. Failure of prophylactic indomethacin to improve the outcome of the very low birth weight infant
31. Auswirkungen einer frühtherapie mit indomethazin auf die manifestation eines persistierenden ductus arteriosus bei extrem untergewichtigen frühgeborenen
32. Prophylactic treatment of asymptomatic patent ductus arteriosus in premature infants with respiratory distress syndrome
33. Early versus late selective treatment of patent ductus arteriosus in preterm infants with respiratory distress syndrome
34. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants
35. Indomethacin for closure of patent ductus arteriosus in prematures
36. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants
37. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus - A double-blind controlled study
38. Indomethacin treatment for symptomatic patent ductus arteriosus: A double blind-control study
39. Early closure off the patent ductus arteriosus in very low-birth-weight infants: A controlled trial
40. Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: A double blind trial
41. Effects of indomethacin in premature infants with patent ductus arteriosus: Results of a national collaborative study
42. Statistical methods for analysis of effects of treatment in overviews of randomised trials
43. Low superior vena cava flow and intraventricular haemorrhage in preterm infants
44. Prevention of periventricular hemorrhage
45. Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the multicenter indomethacin intraventricular hemorrhage prevention trial
46. The effect of indomethacin on the ductus arteriosus assessed by objective ultrasound criteria. Meeting of the Australian Perinatal Society
47. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus
48. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity
49. Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants
50. Effects of indomethacin on cerebral haemodynamics in very preterm infants
51. Continuous versus multiple rapid infusions of indomethacin: Effects on cerebral blood flow velocity
52. Surgical and medical experience with 734 premature infants with patent ductus arteriosus
53. Surgical closure of the patent ductus arteriosus in the neonatal intensive care unit
54. Closure of the patent ductus arteriosus with ligation and indomethacin: A consecutive experience
55. Treatment of patent ductus arteriosus with ibuprofen
56. Ibuprofen for early treatment of patent ductus arteriosus, a randomized multicenter trial
57. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus
58. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants
59. Effect of fluid administration on the development of symptomatic patent ductus arteriosus and congestive heart failure
60. Water balance in very low-birth-weight infants: Relation to water and sodium intake and effect on outcome
61. Fluid restriction for preventing bronchopulmonary dysplasia? Reduced fluid intake during the first weeks of life improves the outcome of low-birth-weight infants